Endometriosis Trials are showing promise for those suffering!
Endometriosis is a difficult condition to manage. There is often a delay in diagnosis and ultimately treatments that are poorly effective or carry substantial side effects. AbbVie has been developing elagolix as an oral alternative to help control the symptoms of endometriosis. The press release below offers insight to the results to date.
Top-line results from the first of two ongoing AbbVie Phase 3 endometriosis trials have been reported in a Press Release, dated January 8, 2015. See attached link.
The Lafayette Clinical Research Group is a dedicated research center with a highly credentialed team focused on the well being of the subjects in clinical research. If you would like to learn more about AbbVie’s Solstice trial you may call us at (765) 269-7134 and ask for Teresa.